Cargando…
Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?
INTRODUCTION: Monoclonal antibodies targeting interleukin 5 (IL5) or its receptor (IL5R) are frequently used in severe asthma, in which they reduce exacerbations rate and oral corticosteroids (OCS) exposure. Anti-IL5/IL5Rs have been studied in patients with chronic obstructive pulmonary disease (COP...
Autores principales: | Laroche, Jérémy, Pelletier, Geneviève, Boulay, Marie-Ève, Côté, Andréanne, Godbout, Krystelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167963/ https://www.ncbi.nlm.nih.gov/pubmed/37180748 http://dx.doi.org/10.2147/COPD.S370165 |
Ejemplares similares
-
Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series
por: Pelletier, Geneviève, et al.
Publicado: (2022) -
Oral Corticosteroids Tapering in Severe Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2021) -
Targeting IL-5 in COPD
por: Narendra, Dharani K, et al.
Publicado: (2019) -
Precision medicine in COPD: where are we and where do we need to go?
por: Sidhaye, Venkataramana K., et al.
Publicado: (2018) -
Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
por: Drick, Nora, et al.
Publicado: (2022)